On June 21st, Dr Bohn received the highly esteemed title of ‘Chevalier de l’Ordre de Mérite du Grand-Duché de Luxembourg’ from the Grand Duke of Luxembourg for his contributions to the culture of Luxembourg.

Hypoxia, or the inadequate oxygenation of a tissue, is a condition occurring frequently in all solid tumours such as melanoma skin cancer. Melanoma cells are not only able to survive oxygen deprivation, but also to use it to their own advantage by hijacking the anti-tumour immune response and developing resistance mechanisms to conventional anti-cancer therapies. A key gene responsible for cancer cell adaptation to hypoxia is HIF-1α (Hypoxia Inducible Factor-1 alpha). Led by Dr Bassam Janji, head of the Tumor Immunotherapy and Microenvironment (TIME) research group at the Luxembourg Institute of Health (LIH) and in collaboration with Gustave Roussy Cancer Center in France and the Thumbay Research Institute of Precision Medicine at Gulf Medical University in the United Arab Emirates, the team used gene editing technologies to show how targeting HIF-1α could not only inhibit tumour growth, but also drive cytotoxic (toxic to cells) immune cells to the cancer tissue. This discovery provided a valuable new target to make resistant melanomas more vulnerable to available anti-cancer treatments. Their findings were recently published in the reputable ‘Oncogene Journal’.

Dr Martyna Szpakowska, scientist within the Immuno-Pharmacology and Interactomics group of the Department of Infection and Immunity (DII) and the Tumor Immunotherapy and Microenvironment group of the Department of Oncology (DONC), was awarded a EUR 10,000 grant under the LIH Wolfgang Baertz Career Launchpad Award (Legs W. Baertz) programme at the end of May 2021. The funding will allow her to develop an innovative type of antibody that targets and neutralises a receptor with a newly-discovered role in the infiltration of cytotoxic immune cells in the tumour microenvironment and in subsequent tumour recession. This transversal and translational project, has the potential to significantly advance cancer immunotherapies

Digitalisation is moving forward fast in every field, including medicine. But how can digital tools be integrated into healthcare processes, and how should data be visualised to personalize patient care? These are only two of many questions that Professor Dr Jochen Klucken will analyse over the upcoming five years. Supported by a 3.3 MEUR FNR PEARL Chair, Prof. Dr Klucken will develop digital health concepts for Luxembourg through a joint research programme involving the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg, the Luxembourg Institute of Health (LIH) and the Centre Hospitalier de Luxembourg (CHL).

A collaborative effort from the Luxembourg Institute of Health (LIH), the University of Western Ontario (Canada), Aarhus University (Denmark), the Steno Diabetes Center Aarhus (Denmark), the Centre Hospitalier de Luxembourg (CHL) and the Directorate of Health (Luxembourg), led by Dr Gloria A. Aguayo from the LIH Department of Population Health (DoPH), was the first to show a link between poor sleep quality and duration, and impaired glycaemic control. The results, published in Diabetes & Metabolism in May 2021, highlight the relevance of measuring sleep patterns as key factors in the prevention of diabetes.

National PhD Welcome Day

WEBINAR: Lecture series Cancer Research: "Metabolic perturbations and human disease phenotypes" - Prof Ralph DeBerardinis

Building on their previous findings, scientists from the Immuno-Pharmacology and Interactomics group at the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH), in collaboration with the Center for Drug Discovery at RTI International (RTI), a nonprofit research institute, have demonstrated that conolidine, a natural painkiller derived from the pinwheel flower and traditionally used in Chinese medicine, interacts with the newly identified opioid receptor ACKR3/CXCR7 that regulates opioid peptides naturally produced in the brain. The researchers also developed a synthetic analogue of conolidine, RTI-5152-12, which displays an even greater activity on the receptor. These findings, which were published on June 3rd in the prestigious international journal ‘Signal Transduction and Targeted Therapy’ (Nature publishing group), further advance the understanding of pain regulation and open alternative therapeutic avenues for the treatment of chronic pain.

On May 20th 2021, the Luxembourgish non-profit association “Schëfflenger Kriibshëllef” made a donation to the LIH Department of Oncology (DONC) to support the acquisition of new laboratory equipment for cancer research.